Among the participants, 53 patients (89.8%) experienced treatment‐related adverse events (TRAEs), with the most common being proteinuria (33.9%), aspartate aminotransferase elevation (27.1%), white blood cell count decrease (22.0%), alanine aminotransferase elevation (20.3%), and anemia (20.3%). The gene discussed is GPT; the disease is anemia.